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Abstract
Background: Urinary tract infections (UTIs) are the second most common bacterial infections in general practice
and a frequent indication for prescription of antimicrobials. Increasing concern about the association between the
use of antimicrobials and acquired antimicrobial resistance has highlighted the need for rational pharmacotherapy
of common infections in general practice.
Methods: Management of urinary tract infections in general practice was studied prospectively over 8 weeks.
Patients presenting with suspected UTI submitted a urine sample and were enrolled with an opt-out methodology.
Data were collected on demographic variables, previous antimicrobial use and urine samples. Appropriateness of
different treatment scenarios was assessed by comparing treatment with the laboratory report of the urine sample.
Results: A total of 22 practices participated in the study and included 866 patients. Bacteriuria was established for
21% of the patients, pyuria without bacteriuria for 9% and 70% showed no laboratory evidence of UTI. An
antimicrobial agent was prescribed to 56% (481) of the patients, of whom 33% had an isolate, 11% with pyuria
only and 56% without laboratory evidence of UTI. When taking all patients into account, 14% patients had an
isolate identified and were prescribed an antimicrobial to which the isolate was susceptible. The agents most
commonly prescribed for UTI were co-amoxyclav (33%), trimethoprim (26%) and fluoroquinolones (17%). Variation
between practices in antimicrobial prescribing as well as in their preference for certain antimicrobials, was
observed. Treatment as prescribed by the GP was interpreted as appropriate for 55% of the patients. Three
different treatment scenarios were simulated, i.e. if all patients who received an antimicrobial were treated with
nitrofurantoin, trimethoprim or ciprofloxacin only. Treatment as prescribed by the GP was no more effective than
treatment with nitrofurantoin for all patients given an antimicrobial or treatment with ciprofloxacin in all patients.
Prescribing cost was lower for nitrofurantoin. Empirical treatment of all patients with trimethoprim only was less
effective due to the higher resistance levels.
Conclusions: There appears to be considerable scope to reduce the frequency and increase the quality of
antimicrobial prescribing for patients with suspected UTI.
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Background
Urinary tract infections (UTIs) are the second most
common bacterial infections in general practice and a
frequent indication for prescription of antimicrobials [1].
Antimicrobial resistance in urinary pathogens, particu-
larly E.coli, is directly associated with prescribing in
primary care [2]. Increasing concern about the associa-
tion between the use of antimicrobials and acquired
antimicrobial resistance has highlighted the need for
rational pharmacotherapy of common infections in gen-
eral practice [3].
Diagnosis of UTI often requires laboratory examina-
tion of a urine sample in addition to clinical evaluation.
Although many guidelines indicate that the culture of
urine is not required in most cases of uncomplicated
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any medium, provided the original work is properly cited.cystitis, the laboratory in this region accepts all such
requests from the GP and many GPs choose to send
samples on all patients with suspected UTI [4,5]. For
patients with symptomatic UTI empiric antimicrobial
treatment is generally recommended while culture and
susceptibility results are pending. Pyuria is an expected
accompaniment of significant bacteriuria. The absence
of pyuria is considered useful in excluding UTI [6].
However, pyuria accompanying asymptomatic bacter-
iuria is not of itself an indication for antimicrobial treat-
ment [7]. Trimethoprim and nitrofurantoin are the
agents generally recommended for empiric therapy of
uncomplicated UTI although acquired resistance to tri-
methoprim in E.coli may limit the use of this agent for
empiric treatment in many areas [7-9].
Even though UTI is a very common diagnosis, man-
agement of this condition is not consistent in general
practice [3,10]. The aim of our study was to describe
the current management of UTI in general practice
including the evaluation of appropriateness of the anti-
microbial treatment in relation to the laboratory results.
Methods
The mainly rural population served by the laboratory is
approximately 230,000 individuals within 72 general
practices. The laboratory of the Galway University Hos-
pitals (GUH) analyses all urine samples from the prac-
tices in this region. The study required that practices
submitted samples for every patient with suspected UTI
on clinical grounds. In order to minimise the study
impact on laboratory workload and established GP prac-
tice, practices with already high numbers of submitted
samples were invited to participate. Practices were
ranked according to the number of submitted urine
samples in 2007 and based on samples size calculations,
economic and time constraints, the 25 highest ranking
practices were invited to participate in the study. Of
these, 22 practices participated, two practices were not
included as they did not have computerised records and
one practice declined (they never participated in
research).
From the 14th of September to the 9th of November
2009 (8 weeks) practices were requested to send a urine
sample from all adult patients presenting with symp-
toms of urinary tract infection. Notices outlining the
study were put up in all practice waiting and consulta-
tion rooms. A website was set up with information on
antimicrobial resistance and detailed information on the
study (http://www.antibiotics.nuigalway.ie). All adult
patients (≥18 years of age) from whom a urine sample
was received in the laboratory were informed of the
study by a letter explaining the study. Patients could
opt-out of the study by returning the included (freepost)
opt-out form, by filling in the opt-out form on the
website or by telephone. All practices were visited and
the charts of all participating patients were viewed for
information on demographic variables and all antimicro-
bial prescribing in the year previous to the urine sam-
ples was recorded. Patients with indwelling catheters
and pregnant women were excluded from the study.
Ethical approval was obtained from the Research
Ethics Committee of the Irish College of General Practi-
tioners. More detail on the ethical approval, the selec-
tion of practices as well as on the inclusion of patients
has been described in a previous paper [11].
The receiving laboratory is accredited to the ISO
15189 quality standard. Laboratory diagnosis was based
on microscopy and semi quantitative culture of a urine
sample. Pyuria was defined as the presence of increased
leukocytes (greater than 20 white cells/μl) in the urine.
For the purpose of this study, bacteriological confirma-
tion of UTI was defined as a pure or predominant
growth of relevant organisms at the level of 10
5 colony
forming units (cfu) per ml [12]. Antimicrobial suscept-
ibility testing was performed in accordance with the disk
diffusion method of the Clinical and Laboratory Stan-
dards Institute (CLSI) [13]. For further statistical analy-
sis, samples with intermediate resistance were
categorised as resistant.
Antimicrobial prescriptions were recorded according
to the major groups: penicillins, b-lactam/b-lactamase
inhibitor combinations, cephalosporins, trimethoprim,
fluoroquinolones (including nalidixic acid and fluoroqui-
nolones such as ciprofloxacin), tetracycline, nitrofuran-
toin and macrolides. Information on previous urine
samples was also included. Other variables available for
patients were age, gender, number of visits in the pre-
vious year (more or less than 10). Medical card eligibil-
ity depends on income and age and can be interpreted
as a proxy measure of socio-economic status. At the
time of the study, about 30% of the population was eligi-
ble for a medical card including all pensioners over the
age of 70 years. Medical card patients have free medical
care and medication while other (private) patients pay
for both.
For each patient the first visit during the study period
at which a urine sample was obtained, was used as the
index visit. The antimicrobial therapy prescribed in a
period of 7 days around the date of the sample, was
identified to be the medication given for this episode,
with the closest prescription to the date of urine collec-
tion regarded as the initial prescription.
Appropriateness of different treatment approaches was
assessed by evaluating the treatment prescribed by the
GP with the subsequent laboratory report of the urine
sample. Overall, antimicrobial prescription for patients
without bacteriological confirmation of infection was
considered inappropriate. The prescription of an
Vellinga et al. BMC Family Practice 2011, 12:108
http://www.biomedcentral.com/1471-2296/12/108
Page 2 of 10antimicrobial to which the cultured organism was resis-
tant was also considered inappropriate. Appropriate
treatment included not prescribing an antimicrobial to
patients with a negative culture and treating patients
with an isolate susceptible to the antimicrobial pre-
scribed. The antimicrobial prescriptions for patients
with an isolate which was not E.coli were individually
assessed. A simulation of different treatment options, i.e.
if all patients who received an antimicrobial were treated
with nitrofurantoin, trimethoprim or ciprofloxacin, is
also presented. Based on the relative numbers of E.coli
in each treatment group, an additional analysis was per-
formed to assess at what trimethoprim resistance level
the trimethoprim scenario would reach similar levels of
appropriate treatment as nitrofurantoin and fluoroqui-
nolones. The price of treatment was calculated from the
average price of all the prescriptions of these practices
for this antimicrobial group. Prices were according to
the manufacturing cost of the medicine as recorded in
the HSE-PCRS (year 2010).
Statistical analysis was performed with SPSS (version
18.0) for univariate comparisons and WinPepi for the
comparison of proportions [14].
Results
A total of 1361 urine samples were submitted from 1163
patients of whom 145 (12.5%) opted out of the study
and 152 (13%) patients did not meet the eligibility cri-
teria. Of the 866 eligible patients the mean age was 52.4
years (95% CI 51.0-53.8, ranging from 18-100) and
77.9% were females. For 183 out of the 866 patients
UTI was confirmed by culture (21%), mainly E.coli (147
or 80.3%). Other organisms identified were Proteus spp.
(9), other Enterobacteriaceae (8) Staphylocccus saprophy-
ticus (6), Enteroccus spp. (5) and eight other species.
Pyuria was detected in 76 (8.8%) patients and 607
(70.1%) patients showed no laboratory evidence of UTI.
An antimicrobial was prescribed to 56% of the
patients (481). An overview of antimicrobial prescribing
is shown in table 1. Co-amoxyclav (33.1%) and tri-
methoprim (26.0%) were most often prescribed, fluoro-
quinolones represented 17% of the prescriptions and
nitrofurantoin nearly 12%. In two cases it was not possi-
ble to determine from the record which antimicrobial
agent was prescribed. More than half of the antimicro-
bials prescribed (55.7%) were for patients with no
laboratory evidence of UTI and 11% were for patients
with pyuria only. In total 179 of the patients (37% of all
prescriptions) received a recommended first line antimi-
crobial (nitrofurantoin or trimethoprim).
Of the 158 patients with bacteriological confirmation
of infection, the antimicrobial susceptibility was known
and compared with the antimicrobial therapy prescribed.
Co-amoxyclav was prescribed 51 times but for 10 of
those the isolated organisms was resistant (20%) to co-
amoxyclav, for ampicillin 6 out of 8 prescriptions (75%)
were for patients with ampicillin resistant organisms, for
trimethoprim 18 out of 50 (36%), for ciprofloxacin 2 out
of the 20 (10%) and for nitrofurantoin 2 out of 22 pre-
scriptions (9%) were prescribed for an infection with a
nitrofurantoin resistant organism. No nitrofurantoin was
prescribed for Proteus spp. In total 37 out of 158
patients (23%) were prescribed an agent to which the
isolate cultured was resistant. When taking all records
into account, 121 out of 866 patients (14.0%) had a
laboratory confirmed UTI and were prescribed an
appropriate antimicrobial to which the isolate was sus-
ceptible. A flow chart of the isolates included in the
study is shown in Figure 1.
Practice differences
Practices showed preferences for certain antimicrobials
and prescribing differed considerably between practices.
An overview of practice prescribing is shown in Figure
2. The percentage of the patients receiving any antimi-
crobial therapy ranged between 39% and 78% between
practices. Some practices mainly prescribed trimetho-
prim and nitrofurantoin, according to the recommended
first line treatment of UTI; practice 18, practice 22 and
practice 1, while other practices predominantly prescribe
fluoroquinolones (practice 14).
Participating practices were compared with non-parti-
cipating practices for the available variables from the
laboratory (percentage female and mean age of patients,
percentage E.coli positive samples and percentage resis-
tance for each antimicrobial) and showed no significant
differences (t-test, comparing means, results not shown).
Appropriateness of treatment
An antimicrobial treatment was prescribed to 481 of the
866 patients included in this study, the two unknown
antimicrobial therapies were interpreted as appropriate.
The appropriateness of treatment was evaluated against
t h el a b o r a t o r yr e p o r to nt h eu r i n es a m p l ea n di n t e r -
preted as appropriate for 55% of the patients (table 2).
Additionally, the appropriateness of three specific sce-
narios was assessed; all antimicrobial prescriptions were
nitrofurantoin (scenario 1), trimethoprim (scenario 2) or
ciprofloxacin (scenario 3). The analyses of these scenar-
ios showed that treatment as prescribed by the GP, the
nitrofurantoin only and the ciprofloxacin only scenario
reached similar levels of appropriately treated patients
(Comparison of proportions of two independent groups
[14], no significant difference). The medication cost was
lower for the nitrofurantoin only scenario, the ciproflox-
acin only scenario resulted in the highest medication
cost and the actual GP prescribing was intermediate.
Additional use of urine dipstick to exclude prescribing
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resulting from an infection with Proteus spp.f o rw h i c h
nitrofurantoin would be considered inappropriate treat-
ment) could further increase the appropriateness of
treatment of UTI with nitrofurantoin ([15]. Empirical
treatment of all patients with trimethoprim only was
less often appropriate due to the higher resistance levels.
The additional analysis of the trimethoprim only sce-
nario at different trimethoprim resistance levels resulted
in 57.4% of patients appropriately treated when at resis-
tance levels for trimethoprim of 10% (Figure 3) but fall
below that with increasing trimethoprim resistance
levels.
Discussion
Overview of the results
Overall, only 1 in 5 urine samples of patients with sus-
pected UTI have bacteriological confirmation of UTI by
the criteria applied in this study. A high proportion of
patients (481 or 56%) were treated with antimicrobials.
Of these 481 patients, 56% (268) had no laboratory evi-
dence of UTI and a further 11% (55) of these patients
have pyuria but no significant bacteriuria. A number of
these prescriptions were not appropriate because the
organism was resistant or because the treatment was not
appropriate for the infection with the organism identified
in the urine culture. Recommended first line treatment
was prescribed for just 38% of patients (trimethoprim or
nitrofurantoin). Treatment of UTI in general practice
shows important variation between practices and clear
practice preferences for certain antimicrobials. This was
most striking for fluoroquinolones, which is the prescrip-
tion of first choice in some practices, and which was pre-
scribed to 17% of all patients in the study.
Of all patients in the study, 56% received treatment
that was classified as appropriate; no treatment when
Table 1 Overview of antimicrobial therapy at the index visit according to the microscopy result of the urine sample
Community resistance level in 2009 (E.coli only) no organism, no pyuria Pyuria organism Total
Co-amoxyclav 30.5% N 87 21 51 159
% of total 18.1% 4.4% 10.6% 33.1%
% within 54.7% 13.2% 32.1%
Ampicillin 68.1% N 18 1 8 27
% of total 3.7% 0.2% 1.7% 5.6%
% within 66.6% 3.7% 29.6%
Trimethoprim 30.5% N 60 15 50 125
% of total 12.5% 3.1% 10.4% 26.0%
% within 48.0% 12.0% 40.0%
Fluoroquinolone 8.3% N 54 8 20 82
% of total 11.2% 1.7% 4.2% 17.0%
% within 65.9% 9.8% 24.4%
Nitrofurantoin 4.1% N 29 6 22 57
% of total 6.0% 1.2% 4.6% 11.9%
% within 50.9% 10.5% 38.6%
Other N 20 4 7 31
% of total 4.2% 0.8% 1.5% 6.4%
% within 64.5% 12.9% 22.6%
Total N 268 55 158 481
% of total 55.7% 11.4% 32.8% 100.0%
The number (N) and percentage (% within) of each antimicrobial prescribed is given for patients with no organism or pyuria was identified in the urine sample,
when only pyuria was detected and when an organism was detected. The overall percentage of each antimicrobial prescribed (% of total) is also shown. For
reference, the community antimicrobial resistance levels of all E.coli from urinary samples (no duplicates) analysed in the laboratory of the Galway University
Hospitals during 2009 is presented in the first column.
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case of a laboratory confirmed UTI (14%). If all antimi-
crobial prescriptions by the GP were for nitrofurantoin,
57% of the treatments would have classified as appropri-
ate with a total drug cost that would have been substan-
tially lower than the total cost of the antimicrobial
treatments actually prescribed by the GP. While there
are certain patients for whom nitrofurantoin is not
appropriate [7,8], this finding supports recommenda-
tions for the use of nitrofurantoin as the preferred agent
for empiric therapy in the absence of a specific contrain-
dication. Even though fluoroquinolones also reach this
higher level of appropriateness, the cost of treatment
with fluoroquinolones is nearly 3.5 times higher com-
pared to the nitrofurantoin treatment. In addition, there
are specific concerns related to the widespread use of
fluoroquinolone agents [7,16]. The proportion of E.coli
bloodstream isolates resistant to ciprofloxacin has
increased considerably in Ireland and other European
countries in recent years [17,18]. Blood stream infection
with fluoroquinolone resistant E. coli is associated with
an increased risk of mortality, most likely due to the
delayed adequate antimicrobial therapy [19,20].
Strengths and limitations
The high level of participation of patients due to the
opt-out method of recruitment ensures the reliability of
the study results. This together with the representative-
ness of the participating practices as well as the similar-
ity between the urine submission patterns before and
Figure 1 Flow chart (AM is AntiMicrobial therapy) of the study population and management of UTI in general practice.
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overview of current management of UTI in Irish general
practice.
To assess the appropriateness of therapy, a period of
seven days around the submission of the urine sample
was used. Empirical therapy is initiated before the causa-
tive pathogen is identified and the prescription of anti-
microbial treatment aims to be active against the most
likely pathogens, taking into account local resistance
profiles while not increasing the potential impact on
resistance levels [21]. As it was possible to have the
laboratory results after 3 days and antimicrobial treat-
ment could have been based on these results, patients
with an antimicrobial treatment prescribed between 4
and 7 days after submission were identified. A total of
23 patients received antimicrobial during this window
(out of a total of 481 who received an antimicrobial). Of
these, no organisms was identified for 14 patients even
though they obtained an antimicrobial prescription 4
days after their urine sample was taken, 8 received an
Figure 2 Overview of total and specific antimicrobial prescribing by practice.
Table 2 Overview of the appropriateness of treatment prescribed by the GP and is cost
Treatment option Appropriately treated patients N
(%)
Inappropriately treated patients N
(%)
Cost of
medication
As prescribed by GP 478 (55.2) 388 (44.8) € 3,685 *
Empiric treatment with nitrofurantoin only 498 (57.5) 368 (42.5) € 2,222
Empiric treatment with trimethoprim only 455 (52.5) 411 (47.5) € 2,001
Empiric treatment with fluoroquinolones
only
499 (57.6) 367 (42.4) € 7,691
Three treatment scenarios and their cost are also presented, i.e. if an antimicrobial was prescribed by the GP, what if this prescription was only nitrofurantoin,
trimethoprim or fluoroquinolone.
*2 unknown prescriptions not included
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was changed due to the resistance of the isolate. In
addition to this patient, only one other patient had their
prescription changed due to the E.coli being resistant to
the first treatment.
The categorisation of empirical treatment of UTI as
appropriate or not has limitations as it does not include
a validation against the guidelines for first-line antimi-
crobials [7,8] and considers appropriate the prescription
of agents with a wider spectrum of activity than neces-
sary (ciprofloxacin and co-amoxyclav). To address the
limitation of this approach data on the extent of pre-
scribing of individual antimicrobial agents were included
to show the extent of the overuse of ciprofloxacin and
co-amoxyclav. The gap between recommended practice
(guidelines) and actual clinical practice is common in
primary and hospital care [22,23]. Additional qualitative
work is necessary to study and describe both why this is
h a p p e n i n ga n dw h a ti sr e q u i r e dt oc h a n g es u c h
behaviour.
For bacteriuria a threshold of 10
5/ml was used in this
study and for pyuria a threshold ≥ 20 leucocytes/ml was
defined. Pyuria alone is not a reliable indicator of urin-
ary tract infection as it may be present as a result of
other conditions [12,24]. However, as lower thresholds
for bacteriuria can be used and pyuria in itself may be a
Figure 3 Appropriateness of treatment of UTI with trimethoprim only (appropriately treated patients marked by diagonal pattern).
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tion of the sample, the appropriateness of the treatment
might be underestimated. For the comparison of the
treatments this difference would be expected to be the
same for all organisms and treatment options and
would not affect the conclusions.
How this compares
The high number of participants in this study shows the
success of the op-out methodology. A paper from Ger-
many on management of UTI in female patients [25],
enrolled 585 patients with suspected UTI from 36 prac-
tices over a period of 4 months while Fahy et al. [26]
enrolled 160 patients from 8 practices in Bristol over a
4 month period. An observational study recruited 288
patients from 9 practices and required the GP to enrol
patients and patients to fill out a questionnaire [27] and
obtained 60% response and 39% subsequent participa-
tion. A prospective study with two recruitment arms
obtained 66% participation for patients approached
within the healthcare facility and 41% participation in a
random sample of non attending patients [28]. In a
spotter practice model, clinicians from three general
practices were asked to submit mid-stream urine sam-
ples from all patients presenting with symptoms sugges-
tive of UTI [29]. The percentage of patients with
significant bacteriuria (according to the same laboratory
definition as in our study) was 26%. Additional informa-
tion from a sentinel practice group showed significant
growth in 28% of the urines samples received [30]. Our
results with a high inclusion rate (866 patients over 2
months) and 21% positive urine samples compares
favourably. The high inclusion is partially due to the
fact that the GP’s in our study were not requested to
enrol the patients and neither the patient nor GP were
requested to provide additional information. This addi-
tional information is available from the other studies
which can be seen as the trade off between more
detailed patient information and a more representative
population.
It is clear from our results that decisions on empiric
prescriptions of antimicrobials for UTI are often not
appropriate or suboptimal in the context of the subse-
quent laboratory analysis of urine by culture and micro-
scopy. Additionally, the widely recommended first line
empirical treatment is trimethoprim or nitrofurantoin
[31], which were prescribed to only 37% of the patients.
These guidelines do not contain the limitation included
in other recommendations [7] to avoid trimethoprim
when trimethoprim resistance levels exceed 20% or
when trimethoprim was prescribed in the previous 3
months [32]. A previous publication in this region has
included a caution regarding the use of trimethoprim
because of the high levels observed [9]. The poor
adherence to current recommendations for management
of UTI is also described in a Spanish audit study [33].
Even though this study did not compare the prescription
of the antimicrobial with the laboratory results, they
found that 96% of the women with clinical criteria com-
patible with lower UTI received an antimicrobial and
first line recommended treatment was prescribed to 32%
of the patients. In a Dutch study of 470 patients with
suspected UTI, half of the patients were prescribed first
line antimicrobials and nearly 15% received a prescrip-
tion for fluoroquinolones [34]. In our study, some prac-
tices showed clear preferences for recommended first
line agents while others preferred fluoroquinolones.
Levels of resistance to ciprofloxacin in E.coli increased
in Ireland from 5.3 in 2002 to 8.3% in 2009 [9,35]. Simi-
lar tendencies have been observed in other countries
[36-38] and some countries showed the proportion of
ciprofloxacin resistant E.coli as high as 13%, which war-
rants against its use in uncomplicated UTI [39]. The
reasons for the poor adherence to guidelines were stu-
died in a qualitative study and the results suggested that
the perceived lack of applicability to the practice popula-
tion was the main barrier to implementing the guide-
lines [40].
In addition to overall (increased) prescribing of anti-
microbials and its impact on resistance levels [41], prac-
tice variation in the use of antimicrobials has also
s h o w nt oh a v ea ni m p a c ti na na n a l y s i si nf o u rU K
administrations [42]. The relevance of practice variation
for resistance levels has previously been described by us
in a multilevel analysis of retrospective data from 72
practices over a 4.5 year period. In this analysis it was
shown that the variation in levels of resistance (in uro-
pathogenic E.coli) between practices was higher for
ciprofloxacin than it was for trimethoprim and that both
were associated with overall practice prescribing of the
antimicrobial [35]. It has been suggested that it is likely
that limitation of fluoroquinolone prescribing will curtail
fluoroquinolone resistance levels [43] while limiting tri-
methoprim prescribing is less likely to influence the
more established resistance to trimethoprim [44,45].
Empiric antimicrobial treatment was prescribed to
56% of the patients including 37% of patients without
laboratory evidence of UTI. A surveillance study showed
that more than 80% of the patients presenting with a
suspected UTI in English general practice received an
antimicrobial [46]. A comparable study from Germany
in which similar inclusion criteria as described by us
were used, also found 56% prescribing overall and 22%
of the prescribing was for patients without any evidence
of urinary tract infection [25]. It is clear that there
remains scope for reductions in antimicrobial prescrib-
ing in general practice and symptomatic treatment of
patients with suspected UTI might be an option. A
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free of symptoms after 3 days of placebo [47] and a
recent trial showed no difference between symptomatic
treatment with ibuprofen or ciprofloxacin for uncompli-
cated UTI [48]. A study comparing different antimicro-
bial strategies with placebo in a large UTI trial showed
slightly poorer results for the placebo group [49]. These
results suggest that UTI is often a self-limiting disorder
and symptomatic treatment of uncomplicated UTI
deserves further research. However, when empiric treat-
ment is preferred, preference should be given to nitro-
furantoin in the absence of any specific contraindication.
A recent review comparing different classes of antimi-
crobials for treatment of acute uncomplicated UTI in
women found no differences between trimethoprim,
fluoroquinolones, ß-lactam antibiotics and nitrofuran-
toin for the symptomatic cure of acute uncomplicated
UTI [8]. Nitrofurantoin is an appropriate agent because
of low resistance levels in the community and relatively
low cost. Additionally, a recent analysis of recurrent
infections showed that resistance to nitrofurantoin was
generally low and once detected, decays relatively
quickly [4]. There are theoretical reasons to believe that
it may be less likely to select for antimicrobial resistance
as it is concentrated in urine whereas other agents are
distributed extensively in all body compartments includ-
ing the gastrointestinal tract [50,51].
Conclusion
The treatment of uncomplicated UTI was considered
appropriate for 55% of the patients. Antimicrobial treat-
m e n tw a sp r e s c r i b e dt o5 6 %o fa l lp a t i e n t sw i t ha
recommended first line treatment for 38% of these pre-
scriptions. There appears to be considerable scope to
reduce the frequency of antimicrobial prescribing as
well as improve the quality of antimicrobial prescrip-
tions for patients presenting to GPs with symptoms sug-
gestive of UTI. When an antimicrobial is prescribed
uniform use of nitrofurantoin (except when contraindi-
cated) would reduce drug cost without affecting the
appropriateness of treatment. Trimethoprim is not as
appropriate as resistance levels of uropathogenic E.coli
to trimethoprim in the study region are relatively high.
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